Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ketone doai
Reexamination Certificate
1999-06-11
2001-02-13
Jarvis, William R. A. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ketone doai
C514S681000, C514S865000, C514S456000, C514S458000
Reexamination Certificate
active
06187822
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention pertains to a method for healing a wound in a mammal which comprises the steps of (A) providing a therapeutic wound healing composition comprising a therapeutically effective amount of an inhibitor of mono-adenosine diphosphate-ribosyl transferase to inhibit adenosine diphosphate-ribosylation of vascular endothelial growth factor; and (B) contacting the therapeutic wound healing composition with a wound in a mammal. This invention also pertains to wound healing compositions and to methods for preparing and using the wound healing compositions and the pharmaceutical products in which the therapeutic compositions may be used. This invention further pertains to therapeutic dermatological-wound healing compositions useful to minimize and treat diaper dermatitis and to methods for preparing and using the therapeutic dermatological-wound healing compositions.
2. Description of the Background
The disclosures referred to herein to illustrate the background of the invention and to provide additional detail with respect to its practice are incorporated herein by reference and, for convenience, are referenced in the following text and respectively grouped in the appended bibliography.
Wounds are internal or external bodily injuries or lesions caused by physical means, such as mechanical, chemical, viral, bacterial, or thermal means, which disrupt the normal continuity of structures. Such bodily injuries include contusions, wounds in which the skin is unbroken, incisions, wounds in which the skin is broken by a cutting instrument, and lacerations, wounds in which the skin is broken by a dull or blunt instrument. Wounds may be caused by accidents or by surgical procedures. Patients who suffer major or chronic wounds could benefit from an enhancement in the wound healing process. Wound healing consists of a series of processes whereby injured tissue is repaired, specialized tissue is regenerated, and new tissue is reorganized. Wound healing consists of three major phases: a) an inflammation phase (0-3 days), b) a cellular proliferation phase (3-12 days), and (c) a remodeling phase (3 days-6 months). During the inflammation phase, platelet aggregation and clotting form a matrix which traps plasma proteins and blood cells to induce the influx of various types of cells. During the cellular proliferation phase, new connective or granulation tissue and blood vessels are formed. During the remodeling phase, granulation tissue is replaced by a network of collagen and elastin fibers leading to the formation of scar tissue.
Macrophages play a key role in the induction of angiogenesis in fibroproliferative states, including wound repair, rheumatoid arthritis, and solid tumor development (1-5). Production of angiogenic activity by macrophages depends on the balance of production of positive angiogenic regulators and inhibitors of angiogenesis (6,7,8). Positive angiogenic regulators previously shown to be produced by monocytes and macrophages include the cytokines TNF&agr; and Il-8 (9,10,11); negative regulators include thrombospondin-1, Ifn&ggr;-inducible protein-10 (&ggr;IP-10) and other as yet uncharacterized protein inhibitors (12,13,14). The mechanisms controlling the balance of positive and negative angiogenesis regulators are not well understood. Non-activated monocytes and macrophages exhibit a non-angiogenic phenotype (1,4). Following activation with agents such as interferon-&ggr; and/or endotoxin (LPS), macrophages express angiogenic activity, characterized by the expression of angiogenic cytokines, as well as of inhibitors of angiogenesis (15,16,17,18). Activated cells also produce and release oxygen radicals, nitric oxide (NO) and their derivatives (17,19). These radicals have been shown to play an important role in regulating the angiogenic phenotype of activated macrophages (20,21). Agents such as Ifn&ggr; and LPS, as well as reduced oxygen tension (hypoxia) and elevated lactate levels, induce macrophages to express angiogenic activity (1-3,9,22). Recently, macrophages in vivo have been shown to express vascular endothelial growth factor (VEGF), an endothelial-specific mitogen that is potently angiogenic (18,23-30).
U.S. Pat. No. 5,510,391 (Elson) discloses a method of treating blood vessel disorders of the skin and skin disorders caused by photo-aging comprising: a) coformulating a pharmaceutical composition wherein the composition contains from 0.01% to 50% vitamin K; and b) applying the pharmaceutical composition topically to treat blood vessel disorders of the skin and skin disorders caused by photo-aging. The blood vessel disorders of the skin and skin disorders caused by photo-aging includes actinic and iatrogenic purpura, lentigines, telangiectasias of the face, spider angiomas, spider veins of the face and leg.
SUMMARY OF THE INVENTION
The present invention pertains to a method for healing a wound in a mammal which comprises the steps of:
(A) providing a therapeutic wound healing composition comprising a therapeutically effective amount of an inhibitor of mono-adenosine diphosphate-ribosyl transferase to inhibit adenosine diphosphate-ribosylation of vascular endothelial growth factor; and
(B) contacting the therapeutic wound healing composition with a wound in a mammal.
In a preferred embodiment, the mammal is man. In another preferred embodiment, the inhibitor of mono-adenosine diphosphate-ribosyl transferase is selected from the group consisting of Vitamin K1, Vitamin K2, Vitamin K3, Vitamin K4, Vitamin K5, Vitamin K6, Novobiocin, m-iodo benzyl guanidine, nicotinamide, coumermycin, dicoumarol, and silybin. More preferred inhibitors of mono-adenosine diphosphate-ribosyl transferase are Vitamin K1, Vitamin K3, Novobiocin, and silybin. The inhibitor of mono-adenosine diphosphate-ribosyl transferase is present in the therapeutic wound healing composition in an amount from about 0.1% to about 10%, by weight of the therapeutic wound healing composition. The wound may be selected from the group consisting of pressure ulcers, decubitus ulcers, diabetic ulcers, and burn injuries. The therapeutic wound healing composition may further comprise a pharmaceutically acceptable carrier.
The present invention also pertains to a wound healing composition which comprises:
(A) a therapeutically effective amount of an inhibitor of mono-adenosine diphosphate-ribosyl transferase to inhibit adenosine diphosphate-ribosylation of vascular endothelial growth factor; and
(B) a pharmaceutically acceptable carrier.
The present invention further pertains to a method for treating diaper dermatitis in a human which comprises the steps of:
(A) providing a therapeutic diaper dermatitis wound healing composition comprising:
(a) a therapeutically effective amount of an inhibitor of mono-adenosine diphosphate-ribosyl transferase to inhibit adenosine diphosphate-ribosylation of vascular endothelial growth factor;
(b) a buffering agent to maintain the pH of dermatitis in a range from about 5 to about 8; and
(c) an anti-inflammatory agent; and
(B) contacting the therapeutic diaper dermatitis wound healing composition with diaper dermatitis in a human.
The present invention further pertains to a therapeutic dermatological-wound healing composition useful to minimize and treat diaper dermatitis which comprises a therapeutically effective amount of:
(1) a therapeutic wound healing composition comprising an inhibitor of mono-adenosine diphosphate-ribosyl transferase to inhibit adenosine diphosphate-ribosylation of vascular endothelial growth factor;
(2) a buffering agent to maintain the pH of dermatitis in a range from about 5 to about 8; and
(3) an anti-inflammatory agent.
REFERENCES:
patent: 3940478 (1976-02-01), Kurtz
patent: 4725609 (1988-02-01), Kull, Jr. et al.
patent: 4933288 (1990-06-01), Greenfield
patent: 4957744 (1990-09-01), Valle et al.
patent: 5213813 (1993-05-01), Kornecki et al.
patent: 5215738 (1993-06-01), Lee et al.
patent: 5378461 (1995-01-01), Neigut
patent: 5391376 (1995-02-01), Long, Jr. et al.
patent: 5468484 (1995-11-01
Jarvis William R. A.
Kim Vickie
Muccino Richard R.
University of Medicine & Dentistry of NJ
LandOfFree
Wound treatment through inhibition of adenosine diphosphate... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Wound treatment through inhibition of adenosine diphosphate..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Wound treatment through inhibition of adenosine diphosphate... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2598648